New drug KHN922 aims to shrink advanced tumors in early trial
Disease control
Not yet recruiting
This study tests a new drug, KHN922, in about 276 adults with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug through an IV and be…
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:21 UTC